SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
September 2, 2003
-----------------
Date of Report (Date of earliest event reported)
OSI PHARMACEUTICALS, INC.
-------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 0-15190 13-3159796
---------------- ------- --------------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation) File Number) Identification No.)
58 SOUTH SERVICE ROAD
MELVILLE, NY 11747
----------------------------
(Address of principal executive offices)
(631) 962-2000
------------------------
(Registrant's telephone number, including area code)
N/A
-----------------------------
(Former name or former address,
if changed since last report.)
ITEM 5. OTHER EVENTS
On September 2, 2003 and September 3, 2003, OSI Pharmaceuticals, Inc.,
a Delaware corporation, issued press releases, copies of which are attached
hereto as Exhibit 99.1 and Exhibit 99.2 and incorporated herein by reference.
ITEM 7. EXHIBITS
EXHIBIT NO. DESCRIPTION
----------- -----------
99.1 Press release, dated September 2, 2003.
99.2 Press release, dated September 3, 2003.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: September 3, 2003 OSI PHARMACEUTICALS, INC.
By:/s/ Robert L. Van Nostrand
--------------------------------
Robert L. Van Nostrand
Vice President and Chief Financial
Officer (Principal Financial Officer)
EXHIBIT INDEX
EXHIBIT NO. DESCRIPTION
----------- -----------
99.1 Press release, dated September 2, 2003.
99.2 Press release, dated September 3, 2003.